-
公开(公告)号：US11814657B2
公开(公告)日：2023-11-14
申请号：US17555557
申请日：2021-12-20
Applicant: Protalix Ltd.
Inventor： Lilach Chen Zeltsburg , Ilya Ruderfer , Avidor Shulman , Liat Fux , Yulia Ugortsev , Hagit Neta , Sivan Gelley , Elad Lavee Laviad , Yoseph Shaaltiel
Abstract: Modified DNase I protein in which one or more amino acids of a DNase I protein are modified non-cellularly, are provided. The modified DNase I protein exhibits a DNA hydrolytic activity in the presence of actin and an improved DNA hydrolytic activity compared to a homologous non-modified DNase I protein. Processes of preparing the modified DNase I protein and uses thereof in, for example, reducing a DNA content in sputum and/or in treating a disease or condition associated with excess extracellular DNA in a fluid, secretion or tissue of a subject, are also provided.
-
公开(公告)号：US10087232B2
公开(公告)日：2018-10-02
申请号：US14773349
申请日：2014-03-06
Inventor： Yaron Ilan , Yoseph Shaaltiel , Uri Hanania , Tali Kizhner , Tami Ariel , Svetlana Gingis-Velitski
IPC: A61K39/00 , A61K38/00 , A61K38/16 , C07K14/705 , C07K14/525 , C12N15/82 , A61K9/00 , A61K36/81 , C07K16/24
Abstract: A method of treating a TNF Alpha associated medical condition selected from the group consisting of obesity, metabolic syndrome, diabetes and a liver disease or disorder is provided. The method comprising enterally administering to a subject in need thereof a therapeutically effective amount of plant cells expressing a TNF Alpha polypeptide inhibitor, thereby treating the TNF Alpha associated medical condition.
-
23.发明授权公开(公告)号：US10000551B2
公开(公告)日：2018-06-19
申请号：US14849963
申请日：2015-09-10
Applicant: Protalix Ltd.
Inventor： Yoseph Shaaltiel , Uri Hanania , Tali Kizhner , Tami Ariel , Svetlana Gingis-Velitski , Myriam Golembo
IPC: A61K39/00 , C07K14/705 , A61K38/17 , A61K36/00
CPC classification number: C07K14/7151 , A61K36/00 , A61K38/1793 , C07K2319/02 , C07K2319/30 , C12N15/8257
Abstract: A plant produced chimeric polypeptide is provided. The plant produced chimeric polypeptide comprising:(i) a first domain which comprises a TNF Alpha binding domain of a TNF receptor, and(ii) a second domain which comprises an Fc domain of an immunoglobulin, wherein the first domain and the second domain are N-terminally to C-terminally respectively sequentially translationally fused and wherein the chimeric polypeptide specifically binds TNF Alpha.
-
公开(公告)号：US09708595B2
公开(公告)日：2017-07-18
申请号：US14936720
申请日：2015-11-10
Applicant: Protalix Ltd.
Inventor： Avidor Shulman , Ilya Ruderfer , Tehila Ben Moshe , Talia Shekhter , Yaniv Azulay , Yoseph Shaaltiel , Tali Kizhner
CPC classification number: C12N9/2465 , A61K38/00 , C12Y302/01022
Abstract: Multimeric protein structures comprising at least two alpha-galactosidase monomers being covalently linked to one another via a linking moiety are disclosed herein, as well a process for preparing same, and methods of treating Fabry disease via administration of a multimeric protein structure. The disclosed multimeric protein structures exhibit an improved performance, in terms of enhanced activity and/or a longer lasting activity under both lysosomal conditions and in a serum environment.
-
公开(公告)号：US20170101633A1
公开(公告)日：2017-04-13
申请号：US15117826
申请日：2015-02-09
Applicant: PROTALIX LTD.
Inventor： Yoseph SHAALTIEL , Einat ALMON
IPC: C12N9/42
CPC classification number: C12N9/2434 , A61K38/00 , A61K38/47 , C12N9/2402 , C12N15/8257 , C12Y302/01045
Abstract: A method of maintaining disease stability in a subject having Gaucher's disease following switch from enzyme replacement therapy (ERT) is provided. The method comprising orally administering to the subject a therapeutically effective amount of recombinant glucocerebrosidase (GCD) comprised in plant cells, thereby maintaining disease stability following switch.
-
Patent Agency Ranking
公开(公告)号：US09603906B2
公开(公告)日：2017-03-28
申请号：US14375439
申请日：2013-01-31
Applicant: Protalix Ltd.
Inventor： Yoseph Shaaltiel , Uri Hanania , Tali Kizhner , Yulia Matiuhin , Liat Fux , Avidor Shulman
IPC: A61K38/46 , C12N9/22 , C12N15/82 , A61K9/00 , A61K38/47 , A61K33/06 , A61K45/06 , A61K9/14 , A61K33/14
CPC classification number: A61K38/465 , A61K9/007 , A61K9/0075 , A61K9/14 , A61K33/06 , A61K33/14 , A61K38/47 , A61K45/06 , C12N9/22 , C12N15/8221 , C12N15/8257 , C12Y301/21001 , C12Y302/01052
Abstract: An inhalable pharmaceutical composition for pulmonary administration comprising human DNase I and a liquid carrier and, more particularly, but not exclusively, to methods, liquid pharmaceutical inhalation devices and systems for the therapeutic use thereof are provided.
-
27.发明申请公开(公告)号：US20160095907A1
公开(公告)日：2016-04-07
申请号：US14937939
申请日：2015-11-11
Applicant: Protalix Ltd.
Inventor： Yoseph SHAALTIEL , Gideon BAUM , Daniel BARTFELD , Sharon HASHMUELI , Ayala LEWKOWICZ
CPC classification number: A61K38/47 , A61K9/0053 , A61K36/23 , C07K2319/04 , C12N9/2405 , C12N9/2434 , C12N9/2465 , C12N15/8257 , C12P21/005 , C12Y302/01022 , C12Y302/01045
Abstract: A device, system and method for producing glycosylated proteins in plant culture, particularly proteins having a high mannose glycosylation, while targeting such proteins with an ER signal and/or by-passing the Golgi. The invention further relates to vectors and methods for expression and production of enzymatically active high mannose lysosomal enzymes using transgenic plant root, particularly carrot cells. More particularly, the invention relates to host cells, particularly transgenic suspended carrot cells, vectors and methods for high yield expression and production of biologically active high mannose Glucocerebrosidase (GCD). The invention further provides for compositions and methods for the treatment of lysosomal storage diseases.
Abstract translation: 用于在植物培养物中生产糖基化蛋白质的装置，系统和方法，特别是具有高甘露糖糖基化的蛋白质，同时用ER信号靶向这种蛋白质和/或旁路高尔基体。 本发明进一步涉及使用转基因植物根特别是胡萝卜细胞表达和产生酶活性高甘露糖溶酶体酶的载体和方法。 更具体地，本发明涉及宿主细胞，特别是转基因悬浮的胡萝卜细胞，用于高产量表达和生产生物活性高甘露糖葡糖脑苷脂酶（GCD）的载体和方法。 本发明还提供了用于治疗溶酶体贮积病的组合物和方法。
-
28.发明申请ORAL UNIT DOSAGE FORMS AND USES OF SAME FOR THE TREATMENT OF GAUCHER DISEASE 审中-公开口服单位剂型及其用于治疗高血压病的用途公开(公告)号：US20150023929A1
公开(公告)日：2015-01-22
申请号：US14379547
申请日：2013-02-19
Applicant: Protalix Ltd.
Inventor： Yoseph Shaaltiel , Salit Tzaban
CPC classification number: A61K47/46 , A61K9/0053 , A61K36/23 , A61K38/47 , C07K14/435 , C12N9/2402 , C12Y302/01045 , G01N33/5088
Abstract: A method of treating Gaucher's disease in a subject in need thereof is provided. The method comprising orally administering to the subject a therapeutically effective amount of recombinant glucocerecbrosidase (GCD) comprised in plant cells, wherein said therapeutically effective amount of GCD corresponds to 1-1920 units/Kg/14 days, thereby treating Gaucher's disease. Also provide unit dosage forms which comprise the glucocerecbrosidase (GCD) comprised in plant cells.
Abstract translation: 提供了在有需要的受试者中治疗戈谢病的方法。 该方法包括向受试者口服给予植物细胞中包含的治疗有效量的重组葡糖聚糖苷酶（GCD），其中所述治疗有效量的GCD对应于1-1920单位/ Kg / 14天，从而治疗戈谢氏病。 还提供了包含在植物细胞中的葡糖焦糖苷酶（GCD）的单位剂量形式。
-
公开(公告)号：US20140271577A1
公开(公告)日：2014-09-18
申请号：US14292966
申请日：2014-06-02
Applicant: Protalix Ltd.
Inventor： Yoseph SHAALTIEL , Gideon Baum , Daniel Bartfeld , Sharon Hashmueli , Ayala Lewkowicz
IPC: A61K36/23
CPC classification number: A61K38/47 , A61K9/0053 , A61K36/23 , C07K2319/04 , C12N9/2405 , C12N9/2434 , C12N9/2465 , C12N15/8257 , C12P21/005 , C12Y302/01022 , C12Y302/01045
Abstract: A device, system and method for producing glycosylated proteins in plant culture, particularly proteins having a high mannose glycosylation, while targeting such proteins with an ER signal and/or by-passing the Golgi. The invention further relates to vectors and methods for expression and production of enzymatically active high mannose lysosomal enzymes using transgenic plant root, particularly carrot cells. More particularly, the invention relates to host cells, particularly transgenic suspended carrot cells, vectors and methods for high yield expression and production of biologically active high mannose Glucocerebrosidase (GCD). The invention further provides for compositions and methods for the treatment of lysosomal storage diseases.
Abstract translation: 用于在植物培养物中生产糖基化蛋白质的装置，系统和方法，特别是具有高甘露糖糖基化的蛋白质，同时用ER信号靶向这种蛋白质和/或旁路高尔基体。 本发明进一步涉及使用转基因植物根特别是胡萝卜细胞表达和产生酶活性高甘露糖溶酶体酶的载体和方法。 更具体地，本发明涉及宿主细胞，特别是转基因悬浮的胡萝卜细胞，用于高产量表达和生产生物活性高甘露糖葡糖脑苷脂酶（GCD）的载体和方法。 本发明还提供了用于治疗溶酶体贮积病的组合物和方法。
-
公开(公告)号：US20220106578A1
公开(公告)日：2022-04-07
申请号：US17555557
申请日：2021-12-20
Applicant: Protalix Ltd.
Inventor： Lilach CHEN ZELTSBURG , Ilya RUDERFER , Avidor SHULMAN , Liat FUX , Yulia UGORTSEV , Hagit NETA , Sivan GELLEY , Elad LAVEE LAVIAD , Yoseph SHAALTIEL
Abstract: Modified DNase I protein in which one or more amino acids of a DNase I protein are modified non-cellularly, are provided. The modified DNase I protein exhibits a DNA hydrolytic activity in the presence of actin and an improved DNA hydrolytic activity compared to a homologous non-modified DNase I protein. Processes of preparing the modified DNase I protein and uses thereof in, for example, reducing a DNA content in sputum and/or in treating a disease or condition associated with excess extracellular DNA in a fluid, secretion or tissue of a subject, are also provided.
-
-
-
-
-
-
-
-
-
Search Results
39
records
(took 0.034 seconds)
